| Topical prostaglandin-E1 for the treatment of erectile dysfunction. | |
| | |
MedLine Citation:
|
PMID: 7752328 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study was undertaken as a phase I, placebo controlled, nonblinded investigation of the safety and efficacy of topical prostaglandin-E1 for the treatment of erectile dysfunction. Nine men with erectile dysfunction secondary to spinal cord injury and 1 man with mild arterial insufficiency were enrolled in the trial and underwent color flow Doppler ultrasound of the penis after application of topical prostaglandin-E1 to the penis, scrotum and perineum. Eight men completed all phases of the study. Mean cavernous artery diameter increased from 0.09 to 0.11 cm. (p < 0.05) and mean peak systolic flow velocity increased from 15.4 to 22.8 cm. per second (p < 0.05) using color flow Doppler ultrasound. Peak systolic flow velocity increased in both cavernous arteries in 7 of 10 patients. Clinical erections were observed in 2 patients but they were not present with placebo application. Diastolic blood pressure and heart rate varied after application of prostaglandin-E1 to the genitalia. No patient was symptomatic and no adverse skin effects were observed in the 8 patients completing all phases of the study. In conclusion, topical prostaglandin-E1 appears to be safe and well tolerated after application to the genitalia, and significantly increases blood flow to the penis. Further investigation is being pursued. |
| | |
Authors:
|
E D Kim; K T McVary |
Related Documents
:
|
8250288 - Protection of spermatogenesis against cytotoxic effects of two chemotherapeutic drugs b... 16180578 - A local pathway for increased testosterone supply from the testis to the epididymis, va... 12592418 - Study of the third stage of labor by color doppler sonography. 3389968 - Effect of kallikrein on testicular blood circulation. 2981388 - Esr measurement of dissolved oxygen in 4-day chick embryo blood. 457368 - Ultrasonic transesophageal measurement of hemodynamic parameters in humans. |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Journal of urology Volume: 153 ISSN: 0022-5347 ISO Abbreviation: J. Urol. Publication Date: 1995 Jun |
Date Detail:
|
Created Date: 1995-06-16 Completed Date: 1995-06-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0376374 Medline TA: J Urol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1828-30 Citation Subset: AIM; IM |
Affiliation:
|
Department of Urology, Northwestern University Medical School, Chicago, Illinois, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Cutaneous Adult Alprostadil / administration & dosage*, adverse effects Erectile Dysfunction / drug therapy*, physiopathology, ultrasonography Humans Male Middle Aged Ultrasonography, Doppler, Color |
| Chemical | |
Reg. No./Substance:
|
745-65-3/Alprostadil |
| Comments/Corrections | |
Comment In:
|
J Urol. 1995 Jun;153(6):1841-2
[PMID:
7752330
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta an...
Next Document: Blunt trauma: the pathophysiology of hemodynamic injury leading to erectile dysfunction.